GSK3B and Parkinson disease: Modulating Wnt signaling and GSK3B together may hold potential as a neuroprotective treatment in early stages of PD progression (Castelo-Branco et al., 2004; Momčilović et al., 2014; Moya et al., 2014; Awad et al., 2017; Toledo et al., 2017).